Clinical Trials

A clinical trial is currently evaluating gadoxetate sodium-enhanced magnetic resonance imaging as an imaging biomarker to detect aggressive prostate cancer and castration-resistant prostate cancer. Sponsored by the University of Cincinnati, an academic clinical center, this Early Phase 1 investigation has an unknown recruitment status. Overall, this research underscores the exploratory application of gadoxetate sodium contrast imaging within oncology.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03960788 Unknown status
Cancer of the Prostate|Castration-resistant Prostate Cancer
University of Cincinnati
2018-01-02 Early Phase 1

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Gadoxetate sodium product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Gadoxetate sodium functions as a paramagnetic contrast agent that binds to membrane-bound transport proteins and alters nuclear spin relaxation dynamics of surrounding water protons, resulting in shortened T1 relaxation times and enhanced tissue signal intensity. This modulation of magnetic resonance signal contrast enables precise non-invasive characterization of differential tissue perfusion and cellular uptake, which is relevant for identifying aggressive phenotypes in clinical conditions such as prostate cancer and castration-resistant prostate cancer.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.